ATR

CRYSTAL LAKE, Ill., July 16, 2026--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that the Board declared a quarterly cash dividend of $0.48 per share. The payment date is August 20, 2026, to stockholders of record as of July 30, 2026. As previously announced, Aptar will hold a conference call on Friday, July 31, 2026, at 8:00 a.m. Central Time to discuss the Company’s second quarter results for 2026. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. A replay of the conference call can also be accessed for a limited time on the Investors page of the website. About Aptar Aptar is a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that help improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. Learn more at http://www.aptar.com. This press release contains forward-looking statements, including with regard to the payment of the quarterly cash dividend. Expressions or future or conditional verbs such as "will" are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Se...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider AptarGroup (ATR). This company, which is in the Zacks Containers - Paper and Packaging industry, shows potential for another earnings beat. When looking at the last two reports, this maker of consumer-product dispensing systems has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 2.14%, on average, in the last two quarters. For the last reported quarter, AptarGroup came out with earnings of $1.19 per share versus the Zacks Consensus Estimate of $1.15 per share, representing a surprise of 3.48%. For the previous quarter, the company was expected to post earnings of $1.24 per share and it actually produced earnings of $1.25 per share, delivering a surprise of 0.81%. With this earnings history in mind, recent estimates have been moving higher for AptarGroup. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank. Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. AptarGroup currently has an Earnings ESP of +0.74%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner. We expect the company's next earnings report to be released on July 30, 2026. Investors should note, however, that a negative Earnings ESP reading is not indica...

Greif, Inc. GEF announced a 10.7% hike in its quarterly dividend payout. This is in sync with its long-standing commitment to returning capital to shareholders. Greif will pay the new quarterly dividend of 62 cents on its Class A Common Stock and 93 cents per share on its Class B Common Stock on July 1, 2026, to shareholders of record as of June 17, 2026. The raised dividend takes the company’s dividend yield from the current 3.5% to 3.9%. Greif has a three-year dividend growth rate of 3.8%. It has a payout ratio of 57.8%. Greif’s industry peer Sonoco Products Company SON has a quarterly dividend of 54 cents. Sonoco has a payout ratio of 37.1%. Sonoco’s current indicated annual dividend is one of the highest in the industry at $2.16. GEF’s another peer AptarGroup, Inc. ATR has a quarterly dividend of 48 cents. AptarGroup has a payout ratio of 33.5%. AptarGroup’s current indicated annual dividend is $1.92. At the end of second-quarter fiscal 2026, the adjusted free cash flow improved to $179.3 million from $86.6 million, aided by working capital management and lower cash interest tied to the company’s reduced leverage. Greif ended the quarter with $286.1 million in cash and cash equivalents, and a total debt of $1.01 billion. The increased dividend reflects the company’s strength in free cash flow generation and its balance sheet while investing in high-return organic growth opportunities. Greif remains committed to maintaining leverage below 2.0X. GEF shares have gained 17.7% in the past year against the industry's 12% decline. Image Source: Zacks Investment Research The company currently has a Zacks Rank #3 (Hold). A better-ranked stock from the Industrial Products sector is Tennant Company TNC. TNC sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here. Tennant has an average trailing four-quarter earnings surprise of 40.8%. The Zacks Consensus Estimate for TNC’s 2026 earnings is pinned at $5.15 per share. The company’s shares have gained 19.4% in a year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sonoco Products Company (SON) : Free Stock Analysis Report AptarGroup, Inc. (ATR) : Free Stock Analysis Report Greif, Inc. (GEF) : Free Stock Analysis Report Tennant Company (TNC) : Free Stock A...

Shares of AptarGroup, Inc. ATR have dipped 1% since posting first-quarter 2026 adjusted earnings of $1.19 per share on Thursday. Adjusted earnings declined 8% from $1.30 a year ago on a less favorable mix and pharma-related headwinds. However, the bottom line topped the Zacks Consensus Estimate of $1.15. Quarterly sales rose 10.8% year over year to $983 million and beat the consensus mark of $964 million by 2%. AptarGroup, Inc. price-consensus-eps-surprise-chart | AptarGroup, Inc. Quote Pharma segment sales increased 7.1% year over year to $439 million. The reported figure missed our estimate of $454 million. The reported gain was aided by currency and a small acquisition contribution, while core sales slipped 1% on tougher comparisons in the prescription business. Within Pharma, prescription core sales declined 10% as dispensing systems tied to emergency medicine were pressured by destocking. Offsetting this, consumer healthcare core sales increased 4% on nasal decongestant and eye-care solutions, while injectables delivered 20% core growth. The Pharma segment posted adjusted EBITDA of $146 million compared with the prior-year quarter’s $142 million. We predicted adjusted EBITDA of $140 million for the segment. The Beauty segment’s sales advanced 19% year over year to $364 million. The reported figure beat our estimate of $324 million. Core sales grew 3% as demand improved across fragrance dispensing and select personal care applications, with acquisitions and currency providing additional lift. Profitability in Beauty was softer despite sales growth. Adjusted EBITDA came in at $40 million compared with the prior-year quarter’s $37 million. We predicted adjusted EBITDA of $34.5 million for the segment. The Closures segment’s sales increased 5% to $181 million. The reported figure beat our estimate of $177 million. While product volumes improved, core sales were flat because results were weighed down by the pass-through of lower resin pricing. Margins were notably weaker in the segment. Adjusted EBITDA fell to $23.6 million compared with the prior-year quarter’s $27 million, driven by maintenance issues and temporary plant closures tied to extreme weather in North America, as well as certain investment write-offs. We predicted the segment’s adjusted EBITDA to be $28 million. On a reported basis, diluted earnings per share were $1.12 compared with $1.17 in th...

Shareholders might have noticed that AptarGroup, Inc. (NYSE:ATR) filed its quarterly result this time last week. The early response was not positive, with shares down 4.1% to US$119 in the past week. It was a workmanlike result, with revenues of US$983m coming in 2.8% ahead of expectations, and statutory earnings per share of US$1.12, in line with analyst appraisals. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on AptarGroup after the latest results. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. After the latest results, the seven analysts covering AptarGroup are now predicting revenues of US$3.97b in 2026. If met, this would reflect a modest 2.6% improvement in revenue compared to the last 12 months. Statutory earnings per share are expected to shrink 9.2% to US$5.51 in the same period. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$3.94b and earnings per share (EPS) of US$5.30 in 2026. So the consensus seems to have become somewhat more optimistic on AptarGroup's earnings potential following these results. Check out our latest analysis for AptarGroup The consensus price target was unchanged at US$163, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic AptarGroup analyst has a price target of US$220 per share, while the most pessimistic values it at US$144. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure. One way to get more context on these forecasts is to look at how they c...

This article first appeared on GuruFocus. Reported Sales Increase: 11% increase in reported sales. Core Sales: Flat compared to the prior year, adjusting for currency effects and acquisitions. Adjusted EBITDA: $189 million, a 3% increase from the prior year. Adjusted EBITDA Margin: 19.2%, down from 20.7% in the prior year. Adjusted Earnings Per Share: $1.19, compared to $1.30 in the prior year at comparable exchange rates. Pharma Segment Core Sales: Decreased 1%, with a 3% negative impact from emergency medicine dispensing systems. Consumer Healthcare Core Sales: Increased 4%. Injectables Core Sales: Increased 20%. Beauty Segment Core Sales: Increased 3%. Personal Care Core Sales: Increased 6%. Closure Segment Core Sales: Flat compared to the prior year. Consolidated Gross Margins: Declined by 210 basis points year over year. SG&A as a Percentage of Sales: Decreased from 17.5% to 17.1% year over year. Free Cash Flow: $53 million for the quarter. Share Repurchases and Dividends: $100 million in share repurchases and $31 million in dividends paid. Cash Balance: $223 million as of March 31. Net Debt: $1.1 billion. Leverage Ratio: 1.43. Q2 Adjusted EPS Outlook: $1.32 to $1.40 per share. Full Year 2026 Capital Investments: Expected to be $260 million to $280 million. Depreciation and Amortization Expense: Expected to be $310 million to $320 million for the full year 2026. Warning! GuruFocus has detected 2 Warning Sign with BAFN. Is ATR fairly valued? Test your thesis with our free DCF calculator. Release Date: May 01, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. AptarGroup Inc (NYSE:ATR) reported an 11% increase in sales, with core sales remaining flat after adjusting for currency effects and acquisitions. The Pharma segment showed strong demand in injectables, with a 20% increase in core sales, driven by elastomeric components for GLP-1 biologics and antithrombotics. Consumer Healthcare core sales increased by 4%, supported by growth in eyecare and nasal decongestant products. The Beauty segment saw a 3% increase in core sales, with strong demand for prestige fragrance pumps and color cosmetics. AptarGroup Inc (NYSE:ATR) maintained a strong balance sheet, ending the quarter with a cash balance of $223 million and a leverage ratio of 1.43. Pharma segment's core sales decreased by 1% due to less favorabl...

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. AptarGroup (ATR) has drawn fresh attention after reporting first quarter 2026 results that topped consensus forecasts for both earnings and revenue, even though net income and earnings per share were lower than a year earlier. See our latest analysis for AptarGroup. Even with the earnings and revenue beat, AptarGroup’s recent share price performance has been weak, with a 30 day share price return decline of 6.1% and a 1 year total shareholder return decline of 20.9%, pointing to fading momentum despite the new product launches and dividend affirmation. If this earnings reaction has you reassessing packaging and materials names, it could be a good moment to broaden your search through 18 top founder-led companies With AptarGroup trading below some estimated intrinsic value measures after an earnings beat but softer profit figures, the key question is whether recent share weakness signals an undervalued compounder or whether the market is already discounting future growth. AptarGroup's most followed narrative sets a fair value of $161.43 against a last close of $119.02, framing the recent share pullback as a discount to its long term cash generation potential under that view. Read the complete narrative. Want to see what kind of revenue mix, earnings path, and future P/E multiple underpin that valuation gap, and how buybacks and margins fit into the story. Result: Fair Value of $161.43 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this depends on legal costs from intellectual property disputes and uncertain demand for emergency medicine delivery systems not eroding the margin and earnings profile that support this thesis. Find out about the key risks to this AptarGroup narrative. The DCF work suggests AptarGroup is trading about 33.4% below an estimated future cash flow value of $178.59, yet the simpler earnings multiple tells a different story. At a P/E of 19.6x versus a fair ratio of 18.5x, the shares screen as expensive, with a richer P/E than both US and global packaging peers. For investors, that mix of DCF upside and premium earnings pricing raises a clear question: which signal deserves more weight? See what the numbers say about this price — find out in our...

AptarGroup (ATR) came out with quarterly earnings of $1.19 per share, beating the Zacks Consensus Estimate of $1.15 per share. This compares to earnings of $1.2 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +3.25%. A quarter ago, it was expected that this maker of consumer-product dispensing systems would post earnings of $1.24 per share when it actually produced earnings of $1.25, delivering a surprise of +0.81%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. AptarGroup, which belongs to the Zacks Containers - Paper and Packaging industry, posted revenues of $982.87 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 1.92%. This compares to year-ago revenues of $887.3 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. AptarGroup shares have added about 0.8% since the beginning of the year versus the S&P 500's gain of 4.2%. While AptarGroup has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for AptarGroup was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list...

CRYSTAL LAKE, Ill., April 30, 2026--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dispensing, dosing and protection technologies, today reported the following first quarter results for the period ended March 31, 2026, as compared to the corresponding period of the last fiscal year. First Quarter 2026 Highlights (Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures) Reported sales increased 11% and core sales were flat Reported net income decreased 8% to $73 million and reported earnings per share decreased 4% to $1.12 Adjusted earnings per share were $1.19, a decrease of 8%, compared to the prior year at constant currency Adjusted EBITDA margin was 19.2% compared to 20.7% in the prior year Returned $131 million to shareholders through share repurchases and dividends Gael Touya named Aptar’s next CEO effective September 1, 2026 "Across the broader Pharma portfolio, we continue to see growing demand in key areas including GLP‑1 therapies, biologics, systemic nasal drug delivery, nasal decongestants, ophthalmic dispensing, and active material solutions. As anticipated, first quarter results were impacted by emergency medicine destocking, with comparisons further challenged by the exceptionally strong prior-year quarter for the prescription division. The injectables division delivered another quarter of strong, double-digit growth. Consumer dispensing also contributed positively, with volume growth across Beauty and Closures, supported by robust demand in prestige fragrance and beverage applications," said Stephan B. Tanda, Aptar President and CEO. First Quarter Results For the quarter ended March 31, 2026, reported sales increased 11% to $982.9 million compared to $887.3 million in the prior year period. Core sales were flat compared to the prior year period. Pharma’s reported sales increased 7% when compared to the prior year period, with a currency contribution of 7%. Excluding acquisitions, core sales declined 1% in the quarter when compared to the prior year period. In the prescription division, sales for dispensing systems declined 10% primarily due to reduced sales in the emergency medicine category, as anticipated, while the pipeline for systemic nasal drug delivery continued to build. Consumer healthcare sales increased 4% on strong n...

Aptar reported Q1 sales up 11% on a reported basis while core sales were flat year-over-year; adjusted EBITDA rose 3% to $189 million but margins fell to 19.2% and adjusted EPS declined to $1.19 from $1.30 a year ago. The Pharma segment suffered an emergency medicine destocking expected to reduce full-year revenue by about $65 million (roughly two-thirds in H1), offsetting growth in injectables and consumer healthcare. Free cash flow more than doubled to $53 million and Aptar returned $131 million to shareholders (including $100 million of buybacks), finished Q1 with $223 million cash and net debt $1.1 billion, guided Q2 adjusted EPS of $1.32–$1.40, and announced Gael Touya will become CEO on Sept. 1. Interested in AptarGroup, Inc.? Here are five stocks we like better. AptarGroup (NYSE:ATR) reported first-quarter 2026 results that management said largely tracked expectations, with currency providing a lift to reported growth while underlying performance reflected mixed conditions tied mainly to an expected destocking cycle in emergency medicine. On the call, President and CEO Stephan Tanda said Aptar is “collaborating closely” with Gael Touya, who is set to become CEO on Sept. 1 following Tanda’s planned retirement later this year. Touya, currently president of Aptar Pharma, joined the call as CEO designate. → Corning Beats Q1 Estimates but Drops 9% on Guidance Miss Executive Vice President and CFO Vanessa Kanu said reported sales increased 11% in the quarter, while core sales (excluding currency and acquisitions) were flat year over year. Adjusted EBITDA rose 3% to $189 million, but adjusted EBITDA margin declined to 19.2% from 20.7% a year earlier, which Kanu attributed “primarily due to less favorable product mix and operational challenges in Beauty and Closures.” Adjusted earnings per share were $1.19, down from $1.30 in the year-ago period at comparable exchange rates. Kanu said the EPS decline reflected higher depreciation and amortization tied to capital investments and acquisitions, as well as interest expense of $17 million, up $6 million year over year due to higher rates on current-year borrowings. She added that the adjusted effective tax rate was 22.6%, compared with 25.8% a year earlier, due to a more favorable mix of earnings and higher excess tax benefits from share-based compensation. → Meta Posted Its Best Sales Growth Since 2021—So Why Did...

CRYSTAL LAKE, Ill. (AP) — CRYSTAL LAKE, Ill. (AP) — AptarGroup Inc. (ATR) on Thursday reported first-quarter net income of $72.7 million. The Crystal Lake, Illinois-based company said it had net income of $1.12 per share. Earnings, adjusted for non-recurring costs and investment costs, were $1.19 per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.15 per share. The maker of consumer-product dispensing systems posted revenue of $982.9 million in the period, which also beat Street forecasts. Three analysts surveyed by Zacks expected $964.4 million. For the current quarter ending in June, AptarGroup expects its per-share earnings to range from $1.32 to $1.40. AptarGroup shares have climbed slightly more than 1% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $123.68, a fall of 18% in the last 12 months. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ATR at https://www.zacks.com/ap/ATR

AptarGroup (ATR) reported Q1 adjusted earnings late Thursday of $1.19 per diluted share, down from $